Select Topic:
Browse by Series:

Treatment Advances in Metastatic CRPC

Panelists: Philippa J. Cheetham, MD, Stonybrook University;Raoul S. Concepcion, MD, Urology Associates, PC; Kenneth M. Kernen, MD, Michigan Urology;
Published: Tuesday, Nov 04, 2014

For High-Definition, Click
Raoul Concepcion, MD, leads the discussion on recent advances in treatment for mCRPC, including checkpoint inhibitors and novel hormonal agents. Neal Shore, MD, explains that checkpoints are in place to regulate T-cell activity and checkpoint inhibitors work by turning off these checkpoints and activating T cells. 

Immunotherapies focus on addressing the patient’s immune system rather than directly treating the cancer itself, remarks Phillippa Cheetham, MD. Immunotherapy may play an especially important role in the treatment of patients with more aggressive disease.

Advances have also been made with regard to antiandrogens. Hormonal agents in development include ARN-509, ODM-201, and galeterone. Oliver Sartor, MD, comments that it is a very exciting time in terms of hormonal therapy and immunotherapy, and trial data will clarify the roles of each of these agents in the treatment of mCRPC.

Slider Left
Slider Right
For High-Definition, Click
Raoul Concepcion, MD, leads the discussion on recent advances in treatment for mCRPC, including checkpoint inhibitors and novel hormonal agents. Neal Shore, MD, explains that checkpoints are in place to regulate T-cell activity and checkpoint inhibitors work by turning off these checkpoints and activating T cells. 

Immunotherapies focus on addressing the patient’s immune system rather than directly treating the cancer itself, remarks Phillippa Cheetham, MD. Immunotherapy may play an especially important role in the treatment of patients with more aggressive disease.

Advances have also been made with regard to antiandrogens. Hormonal agents in development include ARN-509, ODM-201, and galeterone. Oliver Sartor, MD, comments that it is a very exciting time in terms of hormonal therapy and immunotherapy, and trial data will clarify the roles of each of these agents in the treatment of mCRPC.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x